Currentsierra health and lifePolicy 2026T0627K

Sympathetic blockade (celiac plexus, splanchnic, stellate ganglion) injections

Medical policy governing coverage of sympathetic blockade procedures (e.g., celiac plexus, splanchnic, stellate ganglion, superior hypogastric plexus) for UnitedHealthcare Commercial and Individual Exchange benefit plans.

Policy Summary

Payersierra health and life

PolicySympathetic blockade (celiac plexus, splanchnic, stellate ganglion) injections

Policy CodePolicy 2026T0627K

Change TypeNo material change

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain authorization when required and submit documentation showing the indication meets InterQual CP medical necessity criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4CPT codes listed

2Proven / medically necessary

2Unproven / not medically necessary

InterQualExternal criteria referenced

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage by indication

Coverage stance by indication

Medically necessary indications: Sympathetic blockade using a local anesthetic is proven and medically necessary for treating pancreatic cancer with severe abdominal or back pain AND complex regional pain syndrome (CRPS)

Refer to InterQual CP: Procedures, Sympathetic Blockade for detailed clinical criteria.

Unproven / Not medically necessary indications: Sympathetic blockade is unproven and not medically necessary for chronic pancreatitis OR chronic abdominal or back pain

Documented in policy as not medically necessary for these indications.

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required when indicated and is tied to the medical necessity criteria in this policy. Providers should obtain authorization prior to scheduling services when the member's benefit plan requires it.

Obtain prior authorization when member benefit plan requires it
Authorization is contingent on meeting the medical necessity criteria in this policy
Check member-specific plan for prior authorization submission requirements and timeframes

Step Therapy

Prior Treatment Attempts

Neurolytic interventions (e.g., celiac plexus neurolysis or splanchnic nerve ablation) should generally be reserved for patients who have failed appropriate prior treatments. Documented prior treatment attempts demonstrating a stepwise approach are required to establish medical necessity.

Document trials of conservative management (e.g., optimized medical therapy, analgesics, opioid management) and non-neurolytic interventional options when clinically appropriate
For chronic pancreatitis, document failure of endoscopic and/or surgical treatments when applicable per guideline recommendations
Include dates, duration, response to therapy, and reasons for treatment discontinuation or failure

Documentation Required

Documentation & Benefit Verification

Medical records and benefit verification are required for review. Coverage determination is made based on the member's specific benefit plan and applicable laws; having documentation does not guarantee coverage.

Verify member eligibility and benefits prior to service and confirm any plan-specific coverage rules or limitations
Include complete medical records to support the request: history, relevant imaging, prior treatments, pain assessments, and specialist consultation notes
Medical records may be requested to demonstrate that the member meets the clinical criteria; submission of records does not ensure approval

Background

Sympathetic blockade procedures involve injection of anesthetic agents, and sometimes neurolytic agents, to interrupt sympathetic nerve transmission to target plexuses or ganglia (for example, celiac plexus, splanchnic nerves, stellate ganglion, or superior hypogastric plexus). The policy differentiates indications supported by evidence from those that are not; specifically, it identifies chronic pancreatitis and chronic abdominal or back pain as indications for which the procedure is unproven and not medically necessary.

Definitions

Common sympathetic targets and example CPT codes

Stellate ganglionCPT 64510 — Injection, anesthetic agent; stellate ganglion (cervical sympathetic)

Superior hypogastric plexusCPT 64517 — Injection, anesthetic agent; superior hypogastric plexus

Lumbar or thoracic (paravertebral) sympathetic / paravertebral sympathetic blockCPT 64520 — Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)

Celiac plexusCPT 64530 — Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring

Conservative Treatment Requirements

Conservative treatment requirements

Select patients with refractory pain after other treatments; consider risks and uncertain long-term benefit.

Conservative treatment requirement: For chronic pancreatitis, consider sympathetic/neurolytic interventions only in selected patients after failure of other medical, endoscopic, and surgical treatments; discuss unclear outcomes and procedural risks

Guideline sources: IAP/APA/JPS/EPC (2017), ACG (2020), AGA (2022).

Imaging Requirements

Note

Document use of imaging for celiac plexus and other image-guided blocks

Procedures such as celiac plexus block (CPT 64530) may be performed with or without radiologic monitoring; document imaging use when applicable.

CPT 64530 description: "Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring"
If imaging is used, document type of radiologic monitoring provided